Zhao Z, Leong K W
Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
J Pharm Sci. 1996 Dec;85(12):1261-70. doi: 10.1021/js9602812.
Advances in the understanding of the pathogenesis of infectious diseases and cancer immunology have inspired many new approaches to vaccine development. Many subunit antigens and peptides that are effective for vaccination have been discovered. These subunit antigens in tum stimulate synthesis of effective adjuvants to enhance their immunogenicity. Controlled-release technology offers the potential of further improving the efficacy of conventional vaccine formulations by optimizing the temporal and spatial presentation of the-antigens and adjuvants to the immune system. The combination of sustained release and depot effect may also reduce the amount of antigens or adjuvants needed and eliminate the booster shots that are necessary for the success of many vaccinations. This review examines the contribution controlled release technology can make in various areas of vaccination, with an emphasis on tumor vaccines.
对传染病发病机制和癌症免疫学认识的进展激发了许多疫苗开发的新方法。已发现许多对疫苗接种有效的亚单位抗原和肽。这些亚单位抗原进而刺激有效佐剂的合成以增强其免疫原性。控释技术通过优化抗原和佐剂在免疫系统中的时空呈现，提供了进一步提高传统疫苗制剂效力的潜力。缓释和储库效应的结合还可减少所需抗原或佐剂的量，并消除许多疫苗接种成功所必需的加强针。本综述探讨了控释技术在疫苗接种各个领域的贡献，重点是肿瘤疫苗。
